Decade-long bacterial community dynamics in cystic fibrosis airways
- PMID: 22451929
- PMCID: PMC3326496
- DOI: 10.1073/pnas.1120577109
Decade-long bacterial community dynamics in cystic fibrosis airways
Abstract
The structure and dynamics of bacterial communities in the airways of persons with cystic fibrosis (CF) remain largely unknown. We characterized the bacterial communities in 126 sputum samples representing serial collections spanning 8-9 y from six age-matched male CF patients. Sputum DNA was analyzed by bar-coded pyrosequencing of the V3-V5 hypervariable region of the 16S rRNA gene, defining 662 operational taxonomic units (OTUs) from >633,000 sequences. Bacterial community diversity decreased significantly over time in patients with typically progressive lung disease but remained relatively stable in patients with a mild lung disease phenotype. Antibiotic use, rather than patient age or lung function, was the primary driver of decreasing diversity. Interpatient variability in community structure exceeded intrapatient variability in serial samples. Antibiotic treatment was associated with pronounced shifts in community structure, but communities showed both short- and long-term resilience after antibiotic perturbation. There was a positive correlation between OTU occurrence and relative abundance, with a small number of persistent OTUs accounting for the greatest abundance. Significant changes in community structure, diversity, or total bacterial density at the time of pulmonary exacerbation were not observed. Despite decreasing community diversity in patients with progressive disease, total bacterial density remained relatively stable over time. These findings show the critical relationship between airway bacterial community structure, disease stage, and clinical state at the time of sample collection. These features are the key parameters with which to assess the complex ecology of the CF airway.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



References
Publication types
MeSH terms
Substances
Grants and funding
- P30DK034933/DK/NIDDK NIH HHS/United States
- P30 DK027651/DK/NIDDK NIH HHS/United States
- UL1RR024986/RR/NCRR NIH HHS/United States
- R01HG004906/HG/NHGRI NIH HHS/United States
- P30 DK034933/DK/NIDDK NIH HHS/United States
- RC1 HL100809/HL/NHLBI NIH HHS/United States
- R01 HG004906/HG/NHGRI NIH HHS/United States
- 1RC1HL100809-01/HL/NHLBI NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- R01 HG005975/HG/NHGRI NIH HHS/United States
- 1R01HG005975-01/HG/NHGRI NIH HHS/United States
- U01 HL098961/HL/NHLBI NIH HHS/United States
- U01HL098961/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical